0
Abstract: Poster Presentations |

ARMODAFINIL SUSTAINS WAKEFULNESS THROUGHOUT THE DAY IN PATIENTS WITH EXCESSIVE SLEEPINESS WHO ARE OTHERWISE WELL TREATED FOR OBSTRUCTIVE SLEEP APNEA FREE TO VIEW

Max Hirshkowitz, PhD*; Alan Lankford, PhD; Thomas Roth, PhD; Steven C. Chang, PhD; Gregory A. Rippon, MD
Author and Funding Information

Baylor College of Medicine, VMAC Sleep Center, Houston, TX


Chest


Chest. 2008;134(4_MeetingAbstracts):p152001. doi:10.1378/chest.134.4_MeetingAbstracts.p152001
Text Size: A A A
Published online

Abstract

PURPOSE: Notwithstanding appropriate continuous positive airway pressure (CPAP) usage of ≥ 6 hours per night, approximately 52% of patients with obstructive sleep apnea (OSA) continue to experience residual excessive sleepiness (ES). Armodafinil is the longer acting R-enantiomer of racemic modafinil and represents a next generation, non-amphetamine, wakefulness-promoting agent. It was found effective in patients with OSA who have ES despite regular CPAP use. The racemate may require split or higher dosing to sustain clinical benefit across the day. The R-enantiomer lasts 3 times as long as the S-enantiomer and thereby produces higher sustained plasma concentrations later in the day when compared to modafinil. The purpose of these analyses was to test the ability of armodafinil to improve and sustain wakefulness throughout the day when administered once daily.

METHODS: Post hoc analyses of data from a 12-week, multicenter, double-blind, randomized, placebo-controlled study of regular CPAP users with OSA experiencing residual ES (n=395) who received armodafinil (150 or 250 mg) or placebo once daily. Efficacy outcome was the mean sleep latency of the first 5 of 6 20-min Maintenance of Wakefulness Test subtests administered every two hours beginning at 0900.

RESULTS: Armodafinil improved mean sleep latency (0900–1700) with treatment differences of 3.1, 3.5, and 3.3 mins in the 150-mg, 250-mg, and armodafinil combined groups, respectively, compared with placebo at final visit versus baseline (all, nominal P<0.003). At each individual subtest, the armodafinil groups showed greater improvement versus the placebo group. Armodafinil was generally well tolerated.

CONCLUSION: Once-daily adjunctive armodafinil improved the ability to sustain wakefulness throughout the day in CPAP-treated patients with ES associated with OSA.

CLINICAL IMPLICATIONS: Patients with residual ES associated with OSA who regularly use CPAP benefit from sustained wakefulness throughout the day following once daily armodafinil treatment.

DISCLOSURE: Max Hirshkowitz, Grant monies (from industry related sources) Hirshkowitz: Merck, Evotec, Cephalon, Sanofi-Aventis, Sepracor, Takeda, Organon, Vanda. Lankford: Actelion, Arena, Cephalon, Evotec, GlaxoSmithKline, Lilly, Merck, Neurim, Neurocrine, Neurogen, Organon, Pfizer, Respironics, Sanofi-Aventis, Somaxon, Takeda, Transcept, Vanda. Roth: Sanofi-Aventis, Cephalon, GlaxoSmithKline, Neurocrine, Pfizer, Schering-Plough, Sepracore, Somaxon, Syrex, Takeda, TransOral, Wyeth, Xenoport.; Shareholder Steven C.K. Chang; Gregory A. Rippon; Employee Chang: Employee and receiving stock or stock options from Cephalon, Inc. Rippon: Employee and has equity interest.; Consultant fee, speaker bureau, advisory committee, etc. Hirshkowitz: Cephalon, Takeda, Sanofi-Aventis. Lankford: Actelion, Cephalon, Concert, GlaxoSmithKline, Jazz, Neurocrine, Neurocrine, Neurogen, Ovation, Pfizer, Somaxon, Transcept. Roth: Abbott, Actelion, Arena, BTG, Cephalon, Evotec, Intec, Intra-Cellular, Jazz, Merck, Neurim, Neurocrine, neurogen, Organon, Proctor and Gramble, Pfizer, Sanofi-Aventis, Schering-Plough, Sepracor, Shire, Somaxon, Takeda, TransOral, Vanda.; No Product/Research Disclosure Information

Wednesday, October 29, 2008

1:00 PM - 2:15 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543